BEAM Q1 2024 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M-69.4% YoY

Gross Profit

-$77M-1044.6% margin

Operating Income

-$104M-1405.3% margin

Net Income

-$99M-1331.6% margin

EPS (Diluted)

$-1.21

QoQ Revenue Growth

-97.7%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$102M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$446M

Stockholders' Equity

$913M

Cash & Equivalents

$288M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$24M	-69.4%
Gross Profit	-$77M	-$75M	-2.6%
Operating Income	-$104M	-$99M	-5.3%
Net Income	-$99M	-$96M	-2.3%